These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 14724791)
1. Molecular biology of the human immunodeficiency virus: current and future targets for intervention. Krogstad P Semin Pediatr Infect Dis; 2003 Oct; 14(4):258-68. PubMed ID: 14724791 [TBL] [Abstract][Full Text] [Related]
2. New antiretroviral agents: looking beyond protease and reverse transcriptase. Miller MD; Hazuda DJ Curr Opin Microbiol; 2001 Oct; 4(5):535-9. PubMed ID: 11587929 [TBL] [Abstract][Full Text] [Related]
3. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Menéndez-Arias L Antiviral Res; 2013 Apr; 98(1):93-120. PubMed ID: 23403210 [TBL] [Abstract][Full Text] [Related]
4. HIV type 1 integrase inhibitors: from basic research to clinical implications. Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719 [TBL] [Abstract][Full Text] [Related]
5. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation. Sierra-Aragón S; Walter H Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875 [TBL] [Abstract][Full Text] [Related]
6. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher? Garbelli A; Riva V; Crespan E; Maga G Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620 [TBL] [Abstract][Full Text] [Related]
7. Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches. Shet A; Markowitz M Curr Opin Investig Drugs; 2006 Aug; 7(8):709-20. PubMed ID: 16955682 [TBL] [Abstract][Full Text] [Related]
8. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Imamichi T Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086 [TBL] [Abstract][Full Text] [Related]
9. The structural biology of HIV-1: mechanistic and therapeutic insights. Engelman A; Cherepanov P Nat Rev Microbiol; 2012 Mar; 10(4):279-90. PubMed ID: 22421880 [TBL] [Abstract][Full Text] [Related]
10. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations. Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885 [No Abstract] [Full Text] [Related]
11. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930 [TBL] [Abstract][Full Text] [Related]
12. [The HIV replication cycle. Established therapeutic targets and potential targets]. Alcamí J Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():3-10. PubMed ID: 19572419 [TBL] [Abstract][Full Text] [Related]
13. Stages of HIV replication and targets for therapeutic intervention. Tözsér J Curr Top Med Chem; 2003; 3(13):1447-57. PubMed ID: 14529520 [TBL] [Abstract][Full Text] [Related]
14. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813 [TBL] [Abstract][Full Text] [Related]